Cytotoxic activities of some novel benzhydrylpiperazine derivatives by Gurdal, E.E. et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/235750520
Cytotoxic Activities of some Novel Benzhydrylpiperazine Derivatives







Some of the authors of this publication are also working on these related projects:














Middle East Technical University
137 PUBLICATIONS   1,118 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Ece Gürdal on 30 March 2015.
The user has requested enhancement of the downloaded file.
121Original Article
 Gurdal EE et al. Cytotoxic benzhydrylpiperazines … Drug Res 2013; 63: 121–128
 received   27 . 11 . 2012 






Drug Res 2013; 
63: 121–128 © Georg Thieme 
Verlag KG Stuttgart · New York
ISSN 2194-9379
 Correspondence
 E. E. Gurdal, PhD 
 Department of Pharmaceutical 
Chemistry
Faculty of Pharmacy 
 Yeditepe University 
 34 755 Kayisdagi 
 Istanbul 
 Turkey 
 Tel.:  + 90/216/578 00 00-3293 
 Fax:  + 90/216/578 00 68 
 egurdal@yeditepe.edu.tr 
 Key words
 ●  ▶  benzhydrylpiperazine
 ●  ▶  benzoyl chloride
 ●  ▶  sulfonyl chloride
 ●  ▶  cytotoxicity
 ●  ▶  sulphorhodamine B 
 Cytotoxic Activities of some Novel Benzhydrylpiperazine 
Derivatives
 In this study, we reported the synthesis, purifi ca-
tion and characterization of some novel com-
pounds bearing benzhydrylpiperazine backbone. 
Those compounds were tested for their cytotoxic 
activities against hepatocellular (HUH-7), breast 
(MCF-7) and colorectal (HCT-116) cancer cell 
lines with sulphorhodamine B assay. We aimed 
to develop a structure activity relationship for 
benzhydrylpiperazine derivatives in accordance 
with their cytotoxic activity results.
 Materials and Methods
 ▼
 Chemistry
 All chemicals and reagents used in current study 
were analytical grade. The reactions were moni-
tored by thin layer chromatography (TLC) on Merck 
pre-coated silica GF254 plates. Melting points ( °C) 
of the compounds were determined by using a 
Mettler Toledo FP62 capillary melting point appa-
ratus (Mettler-Toledo, Greifensee, Switzerland) and 
are uncorrected. Ultraviolet spectra were recorded 
with Agilent 8453 UV-Visible Spectrophotometer. 
Infrared spectra were recorded on a Perkin-Elmer 
Spectrum One series FT-IR apparatus (Version 
5.0.1, Perkin Elmer, Norwalk, CT, USA), using 
 potassium bromide pellets, the frequencies were 
expressed in cm  − 1 . The  1 H- and  13 C-NMR spectra 
were recorded with a Varian Mercury-400 FT-NMR 
spectrometer  (Varian Inc., Palo Alto, CA, USA), using 
tetramethylsilane (TMS) as the internal reference, 
with dimethylsulfoxide (DMSO-d 6 ) as solvent, the 
chemical shifts were reported in parts per million 
 Introduction
 ▼
 Cancer is the disease resulting from abnormal cells 
with abilities of uncontrolled dividing and invasion 
to other tissues through blood and lymph systems. 
Recently, advanced treatment opportunities are 
unable to overcome the major problems of chemo-
therapy such as drug resistance and severe side 
eff ects due to lack of specifi city. Regarding issues 
lead the researchers to develop varying drug-like 
compounds targeting cancer.
 Benzhydrylpiperazines are popular with their 
antihistaminic activities  [ 1 – 6 ] . Literature search 
reveals many other activities of benzhydryl-
piperazine derivatives including calcium channel 
blocking  [ 7 – 14 ] , dopaminergic  [ 15 – 18 ] , antimi-
crobial  [ 19 – 36 ] , and antiviral  [ 37 ,  38 ] activities.
 Anticancer activity of benzhydrylpiperazines has 
recently become important  [ 39 – 46 ] . Kumar et al. 
has performed cytotoxicity assays to several 
1-benzhydrylpiperazine derivatives substituted 
with variable sulfonyl chlorides, acid chlorides 
and isothiocyanates. These derivatives have 
potent cytotoxicity over breast cancer (MCF-7), 
hepatocellular carcinoma (HepG-2), cervix carci-
noma (HeLa) and colon carcinoma (HT-29) cell 
lines  [ 39 ] . Yarim et al., also synthesized some 
4-chlorobenzhydrylpiperazines substituted with 
variable benzoyl chloride derivatives and reported 
their high cytotoxic activities against liver (HUH-
7, FOCUS, MAHLAVU, HEPG2, HEP3B), breast 
(MCF-7, BT20, T47D, CAMA-1), colon (HCT-116), 
gastric (KATO-3) and endometrial (MFE-296) 
cancer cell lines  [ 40 ] .
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 Affi  liations   1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Yeditepe University, Istanbul, Turkey 
   2   Department of Molecular Biology and Genetics, BilGen, Genetics and Biotechnology Research Center, Faculty of Science, 
Bilkent University, Ankara, Turkey 
 Abstract
 ▼
 This study presents the synthesis of nineteen 
1-(substitutedbenzoyl)-4-benzhydrylpiperazine 
and 1-[(substitutedphenyl)sulfonyl]-4-benzhy-
drylpiperazine derivatives. In vitro cytotoxic 
activities of the compounds were screened 
against hepatocellular (HUH-7), breast (MCF-
7) and colorectal (HCT-116) cancer cell lines by 
sulphorhodamine B assay. Among the test com-
pounds, benzamide derivatives had high cyto-
toxic activity whereas sulfonamide derivatives 
showed variable 50 % growth inhibition (GI50).
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(ppm). Coupling constants were recorded in Hertz (Hz). The mass 
spectra were recorded with a Waters 2695 Alliance Micromass ZQ 
LC/MS instrument (Waters Corp., Milford, MA, USA). Elemental 
analyses were performed on LECO 932 CHNS (LECO-932, St. Joseph, 
MI, USA) instrument and were within  ± 0.4 % of the theoretical 
 values.
 General procedure for preparation of benzhydrole 
derivatives  [ 44 ] 
 10 mmol (2.2 g) benzophenone was dissolved in 10 ml ethanol. 
In a separate fl ask, 11 mmol (0.4 g) sodium borohydride (NaBH 4 ) 
was dissolved in 2 ml ethanol. Sodium borohydride solution was 
slowly added to benzophenone solution with a Pasteur pipette. 
Reaction mixture was allowed to continue stirring for a further 
30 min. For the work up of reaction, 2 ml of concentrated HCl 
was added to a 20 ml ice-water solution. Reaction mixture was 
poured into this ice cold solution slowly with stirring. White 
solid product was collected with vacuum fi ltration and washed 
twice with distilled water. 4-Chlorobenzophenone and 
4,4′- difl uorobenzophenone were also reacted with sodium 
borohydride to give 4-chlorobenzhydrole and 4,4′-difl uoroben-
zhydrole respectively according to above procedure.
 General procedure for preparation of Benzhydryl 
chloride derivatives  [ 47 ] 
 10 mmol (1.84 g) benzhydrole was added to 15 ml of concen-
trated HCl. 10 mmol (1.1 g) anhydrous calcium chloride was 
added to the mixture to be refl uxed at 85 °C for 4 h with stirring. 
After reaction completed, the fl ask was cooled to room tempera-
ture and extracted twice with 20 ml ethyl acetate. Organic layers 
were combined together, washed with brine and water, then 
dried over anhydrous sodium sulfate. Followed by the concen-
tration under vacuo, the product was collected as brown liquid. 
4-Chlorobenzhydryl chloride and 4,4′-difl uorobenzhydryl chlo-
ride were also synthesized from 4-chlorobenzhydrole and 
4,4′-difl uorobenzhydrole according to above procedure.
 General procedure for preparation of 
Benzhydrylpiperazine derivatives  [ 44 ] 
 9 mmol (0.8 g) piperazine was dissolved in dimethylformamide. 
Anhydrous potassium carbonate was added to the solution and 
stirred for 10 min. Followed by the addition of 9 mmol (1.8 g) ben-
zhydryl chloride, reaction mixture was heated at 80 °C for 8 h. After 
completion, dimethylformamide was removed under vacuo, then 
residue was taken in water and extracted with ethyl acetate. 
Organic layer was washed with water and dried over anhydrous 
sodium sulfate. The solvent was evaporated and white solid prod-
uct was obtained. 1-[(4-Chlorophenyl)(phenyl)methyl]piperazine 
and 4,4′-benzhydrylpiperazine were also synthesized from 4-chlo-
robenzhydryl chloride and 4,4′-difl uorobenzhydryl chloride con-
secutively according to above procedure.
 General procedure for preparation of 1-(Substitutedbenzoyl)-
4-[benzhydryl/4-chlorobenzhydryl/4,4′-difl uorobenzhydryl]
piperazine derivatives (5a–5i)
 2 mmol (0.5 g) 1-benzhydrylpiperazine or 1.7 mmol (0.5 g) 
1-[bis(4-fl uorophenyl)methyl]piperazine or 0.9 mmol (0.3 g) 
1-[(4-chlorophenyl)(phenyl)methyl]-piperazine was dissolved 
in 50 mL dry dichloromethane. Reaction fl ask was taken into ice 
bath and triethylamine (triple moles of benzhydrylpiperazine 
derivative) was added to the solution. 10 min later ice bath was 
removed and appropriate benzoyl chloride derivatives (equimo-
lar with benzhydrylpiperazine derivative) were added. Reaction 
was stirred overnight at room temperature. After the reaction 
was completed, solution was extracted in order with water and 
ammonium chloride solution (10 %). Dichloromethane layer was 
washed with water again and dried with anhydrous sodium sul-
phate. The mixture was concentrated in vacuo and product was 
dissolved in ethyl acetate. Column chromatography was applied 
with  n -hexane-ethyl acetate (80:20) mixture in silica gel col-
umn. Only oily products were dissolved in diethylether and HCl 
gas was passed through the solutions to obtain solid hydrochlo-
ride salt of compounds.
 1-(5-Fluoro-2-methylbenzoyl)-4-(diphenylmethyl)
piperazine hydrochloride (5a)
 White, opaque, powdered crystals. Yield: 95 % (0.402 g); m.p.: 
Above 300 °C. UV (MeOH, λ max , nm); 205 (log ε: 5.22), 224 (log ε: 
4.74). FT - IR (KBr, cm  − 1 ); 3 423 (N-H), 3 043 (C-H, aromatic), 
2 955 (C-H, aliphatic), 1 654 (C = O, amide), 1 612 (C = C, aro-
matic), 1 293 (C-N), 1 261 (C-F).  1 H-NMR (DMSO, ppm); 2.13 (s, 
3H, -CH 3 ); 3.2 (bs, 4H, piperazine H 3 , H 5 ); 3.76 (bs, 4H, pipera-
zine H 2 , H 6 ); 5.64 (d, 1H, (Ar) 2 CH-,  J = 8.4 Hz ); 7.12 (t, 2H, diphe-
nyl H 4,4 ′,  J = 8.8 Hz ); 7.26–7.29 (dd, 4H, diphenyl H 3,5,3 ′ ,5 ′,  J 1 = 5.2 Hz, 
J 2 = 2.8 Hz ); 7.31 (d, 1H, phenyl H 4 ,  J = 7.6 Hz) ; 7.37 (d, 1H, phenyl 
H 3 ,  J = 6.8 Hz ); 7.44 (s, 1H, phenyl H 6 ); 7.86–7.92 (dd, 4H, diphe-
nyl H 2,6,2′,6′ ,  J 1 = 10.8 Hz, J 2 = 7.2 Hz ); (12.61 (bs, 1H, N-H salt).  13 C-
NMR (DMSO, ppm); 37.98 (C 25 ); 43.09 (C 14,16 ); 51.49–51.74 
(C 15,17 ); 75.28 (C 7 ); 113.31–113.54 (C 2,6,9,13 ); 116.36–116.56 
(C 3,5,10,12 ); 129.17(C 4 ); 129.55 (C 11 ); 129.97 (C 1 ); 130.73 (C 8 ); 
132.9 (C 21 ); 132.98 (C 22 ); 136.15 (C 24 ); 137.43 (C 20 ); 159.60 
(C 19 ); 162.02(C 23 ); 167.86 (C 18 ). MS (m/z); 389.8 (100 %, M  +  – 
Cl); 167.5 ((C 6 H 5 ) 2 CH⎤  +  ). Anal. calcd. for C 25 H 26 ClFN 2 O (424.94): 
C, 70.66; H, 6.17; N, 6.59. Found: C, 69.77; H, 5.94; N, 6.63.
 1-(2-Bromobenzoyl)-4-[bis(4-fl uorophenyl)methyl]
piperazine hydrochloride (5b)
 White, opaque, powdered crystals. Yield: 35 % (0.3 g); m.p.: 
189.7 °C. UV (MeOH, λ max , nm); 205 (log ε: 5.27), 223 (log ε: 4.49). 
FT - IR (KBr, cm  − 1 ); 3 423 (N-H), 3 006 (C-H, aromatic), 2 924 (C-H, 
aliphatic), 1 643 (C = O, amide), 1 606 (C = C, aromatic), 1 292 (C-N), 
1 232 (C-F).  1 H-NMR (DMSO, ppm); 3.03 (bs, 4H, piperazine H 3 , 
H 5 ); 3.67 (bs, 4H, piperazine H 2 , H 6 ); 5.59 (s, 1H, (Ar) 2 CH-); 7.27–
7.91 (m, 17H, aromatic H’s); 12.8 (bs, 1H, N-H salt). MS (m/z); 
471.92 (90 %, M  +  – Cl), 473.92 (89 %, M + 2), 203.60 (100 %, 
(4-F-C 6 H 5 ) 2 CH⎤  +  ). Anal. calcd. for C 24 H 22 BrClF 2 N 2 O.H 2 O (524.07): 
C, 54.82; H, 4.60; N, 5.33. Found: C, 54.45; H, 4.83; N, 5.50.
 1-(3-Bromobenzoyl)-4-[bis(4-fl uorophenyl)methyl]
piperazine hydrochloride (5c)
 White, opaque, powdered crystals. Yield: 27 % (0.23 g); m.p.: 
151.4 °C. UV (MeOH, λ max , nm); 204 (log ε: 5.09), 223 (log ε: 4.51). 
FT - IR (KBr, cm  − 1 ); 3 425 (N-H), 3 068 (C-H, aromatic), 2 924 (C-H, 
aliphatic), 1 638 (C = O, amide), 1 606 (C = C, aromatic), 1 290 (C-N), 
1 233 (C-F).  1 H-NMR (DMSO, ppm); 3.11 (bs, 4H, piperazine H 3 , H 5 ); 
3.67 (bs, 4H, piperazine H 2 , H 6 ); 5.59 (bs, 1H, (Ar) 2 CH-); 7.27–7.93 
(m, 13H, aromatic H’s); 12.63 (bs, 1H, N-H salt). MS (m/z); 471.91 
(95 %, M  +  -Cl), 473.91 (94 %, M + 2), 203.61 (100 %, (4-F-C 6 H 5 ) 2 CH⎤  +  ). 
Anal. calcd. for C 24 H 22 BrClF 2 N 2 O.H 2 O (524.07): C, 54.82; H, 4.60; N, 
5.33. Found: C, 54.81; H, 4.59; N, 5.60.
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 1-(4-Bromobenzoyl)-4-[bis(4-fl uorophenyl)methyl]
piperazine hydrochloride (5d)
 White, opaque, powdered crystals. Yield: 19 % (0.1654 g); m.p.: 
Above 300 °C. UV (MeOH, λ max , nm); 204 (log ε: 5.23), 224 (log ε: 
4.46). FT - IR (KBr, cm  − 1 ); 3 437 (N-H), 3 008 (C-H, aromatic), 2 950 
(C-H, aliphatic), 1 640 (C = O, amide), 1 606 (C = C, aromatic), 1 290 
(C-N), 1 233 (C-F).  1 H-NMR (DMSO, ppm); 3.09 (bs, 4H, piperazine 
H 3 , H 5 ); 3.68 (bs, 4H, piperazine H 2 , H 6 ); 5.58 (bs, 1H, (Ar) 2 CH-); 
7.15–7.91 (m, 12H, aromatic H’s); 12.69 (bs, 1H, N-H salt). MS 
(m/z); 471.92 (68 %, M  +  – Cl), 473.92 (67 %, M + 2), 203.59 (100 %, 
(4-F-C 6 H 5 ) 2 CH⎤  +  ). Anal. calcd. for C 24 H 22 BrClF 2 N 2 O.H 2 O (524.07): C, 
54.82; H, 4.60; N, 5.33. Found: C, 55.02; H, 4.84; N, 5.62.
 1-(3-Chlorobenzoyl)-4-[bis(4-fl uorophenyl)methyl]
piperazine hydrochloride (5e)
 Yellowish, opaque, powdered crystals. Yield: 47 % (0.3663 g); 
m.p.: 177.5 °C. UV (MeOH, λ max , nm); 204 (log ε: 5.14), 226 (log 
ε: 4.29). FT - IR (KBr, cm  − 1 ); 3 423 (N-H), 3 007 (C-H, aromatic), 
2 925 (C-H, aliphatic), 1 639 (C = O, amide), 1 606 (C = C, aro-
matic), 1 290 (C-N), 1 233 (C-F).  1 H-NMR (DMSO, ppm); 3.13 (bs, 
4H, piperazine H 3 , H 5 ); 3.65–4.44 (m, 4H, piperazine H 2 , H 6 ); 
5.62 (bs, 1H, (Ar) 2 CH-); 7.25–7.97 (m, 12H, aromatic H’s); 12.72 
(bs, 1H, N-H salt). MS (m/z); 427.97 (98 %, M  +  – Cl); 429.96 (32 %, 
M + 2), 203.61 (100 %, (4-F-C 6 H 5 ) 2 CH⎤  +  ). Anal. calcd. for 
C 24 H 22 Cl 2 F 2 N 2 O.H 2 O (480.12): C, 59.88; H, 5.03; N, 5.82. Found: 
C, 59.93; H, 5.06; N, 5.98.
 1-(2-Methoxybenzoyl)-4-[(4-chlorophenyl)(phenyl)
methyl]piperazine (5f)
 White, shiny, needle-shaped crystals. Yield: 33 % (0.140 g); m.p.: 
120 °C. UV (MeOH, λ max , nm); 202 (log ε: 4.78), 275 (log ε: 3.36). 
FT - IR (KBr, cm  − 1 ); 3 029 (C-H, aromatic), 2 996 (C-H, aliphatic), 
1 626 (C = O, amide), 1 602 (C = C, aromatic), 1 296 (C-O), 1 247 
(C-N), 1 000 (C-Cl).  1 H-NMR (DMSO, ppm); 2.18–2.33 (m, 4H, 
piperazine H 3 , H 5 ); 3.63 (m, 2H, piperazine H 2 ); 3.14 (m, 2H, pip-
erazine H 6 ); 3.75 (s, 3H, -OCH 3 ); 4.39 (s, 1H, (Ar) 2 CH-); 6.95 (t, 
1H, benzoyl H 4 ,  J = 7.2 H z); 7.03 (d, 1H, benzoyl H 6 ,  J = 8 Hz ); 7.12–
7.15 (dd, 1H, benzoyl H 3 ,  J 1 = 1.6, Hz, J 2 = 6 Hz ); 7.2 (t, 1H, phenyl 
H 4 ,  J = 7.2 Hz ); 7.3 (t, 2H, phenyl H 3,5 ,  J = 7.2 Hz ); 7.35 (d, 2H, phe-
nyl H 2,6 ,  J = 8 Hz ); 7.38 (t, 1H, benzoyl H 5 ,  J = 1.6 Hz ); 7.39–7.46 
(dd, 4H, 4-chlorophenyl H’s,  J 1 = 7.6 Hz, J 2 = 10.4 Hz ). Anal. calcd. 
for C 25 H 25 ClN 2 O 2 (420.93): C, 71.33; H, 5.99; N, 6.66. Found: C, 
70.78; H, 6.41; N, 6.73.
 1-(3-Nitrobenzoyl)-4-[(4-chlorophenyl)(phenyl)methyl]
piperazine hydrochloride (5g)
 Yellowish orange, opaque, powdered crystals. Yield: 24 % 
(0.112 g); m.p.: 196.1 °C. UV (MeOH, λ max , nm); 203 (log ε: 4.33), 
227 (log ε: 4.02). FT - IR (KBr, cm  − 1 ); 3 423 (N-H), 3 063 (C-H, aro-
matic), 2 924 (C-H, aliphatic), 1 644 (C = O, amide), 1 533 (N = O), 
1 291 (C-N), 1 092 (C-Cl).  1 H-NMR (DMSO, ppm); 3.17 (bs, 4H, 
piperazine H 3 , H 5 ); 3.83 (bs, 4H, piperazine H 2 , H 6 ); 5.59 (s, 1H, 
(Ar) 2 CH-); 7.3–8.5 (m, 13H, aromatic H’s); 12.71 (s, 1H, N-H salt). 
Anal. calcd. for C 24 H 23 Cl 2 N 3 O 3 .H 2 O (490.38): C, 58.78; H, 5.14; N, 
8.57. Found: C, 58.57; H, 5.52; N, 8.64.
 1-(3,4-Dimethoxybenzoyl)-4-[(4-chlorophenyl)(phenyl)
methyl]piperazine (5 h)
 White, opaque, powdered crystals. Yield: 11 % (0.050 g); m.p.: 
148.6 °C. UV (MeOH, λ max , nm); 204 (log ε: 4.59), 276 (log ε: 
3.45). FT - IR (KBr, cm  − 1 ); 3 082 (C-H, aromatic), 2 966 (C-H, 
aliphatic), 1 621 (C = O, amide), 1 583 (C = C, aromatic), 1 268 
(C-O), 1 230 (C-N), 1 027 (C-Cl).  1 H-NMR (DMSO, ppm); 2.31 (bs, 
4H, piperazine H 3 , H 5 ); 3.52 (bs, 4H, piperazine H 2 , H 6 ); 3.75 (s, 
3H, -OCH 3 ); 3.76 (s, 3H, -OCH 3 ); 4.39 (s, 1H, (Ar) 2 CH-); 6.91 (d, 
1H, benzoyl H 5 ,  J = 2.8 Hz ); 6.94 (d, 1H, benzoyl H 6 ,  J = 3.6 Hz ); 6.97 
(s, 1H, benzoyl H 2 ); 7.21 (t, 2H, phenyl H 3,5 ,  J = 7.6 Hz ); 7.31 (t, 1H, 
phenyl H 4 ,  J = 8 Hz ); 7.35 (d, 2H, phenyl H 2,6 ,  J = 8.4 Hz ); 7.4–7.47 
(dd, 4H, 4-chlorophenyl H’s,  J 1 = 8.8 Hz, J 2 = 10 Hz ). Anal. calcd. for 
C 26 H 27 ClN 2 O 3 (450.96): C, 69.25; H, 6.03; N, 6.21. Found: C, 
69.03; H, 6.32; N, 6.30.
 1-(4-Ethylbenzoyl)-4-[(4-chlorophenyl)(phenyl)methyl]
piperazine hydrochloride (5i)
 Yellow, opaque, powdered crystals. Yield: 22 % (0.1 g); m.p.: 
206.4 °C. UV (MeOH, λ max , nm): 204 (log ε: 4.56), 225 (log ε: 
4.11). FT - IR (KBr, cm  − 1 ); 3 422 (N-H), 3 010 (C-H, aromatic), 
2 966 (C-H, aliphatic), 1 634 (C = O, amide), 1 287 (C-N), 1 092 
(C-Cl).  1 H-NMR (DMSO, ppm); 1.15 (t, 3H, -CH 3 ,  J = 8 Hz ); 2.63 (q, 
2H, -CH 2 -,  J = 7.6 Hz ); 3.13 (s, 4H, piperazine H 3 , H 5 ); 3.79 (s, 4H, 
piperazine H 2 , H 6 ); 5.63 (d, 1H, (Ar) 2 CH-,  J = 8.4 Hz ); 7.27–7.90 
(m, 13H, aromatic H’s); 12.63 (s, 1H, N-H salt). Anal. calcd. for 
C 26 H 28 Cl 2 N 2 O.H 2 O (473.43): C, 65.96; H, 6.39; N, 5.92. Found: C, 
66.33; H, 6.73; N, 5.98.
 General procedure for preparation of 
1-[(substitutedphenyl)sulfonyl]-4-[benzhydryl/4-
chlorobenzhydryl/4,4′-difl uorobenzhydryl]piperazines
 1 mmol (0.2575 g) 1-benzhydrylpiperazine, 1.7 mmol (0.515 g) 
1-[bis(4-fl uorophenyl)methyl]piperazine or 0.872 mmol (0.2632 g) 
1-[(4-chlorophenyl)(phenyl)methyl]piperazine was dissolved in 
20 ml dry dichloromethane. Reaction fl ask was taken into ice 
bath and triethylamine (1:3 moles) was added to the solution. 
10 min later, suitable sulfonyl chloride derivative (1:1 mole) was 
added. Ice bath was removed 2 h later and reaction was stirred 
overnight at room temperature. After reaction was completed, 
solution was extracted in order with water and ammonium 
chloride solution (10 %). Dichloromethane layer was washed 
with water again and dried with anhydrous sodium sulphate. 
Solvent was evaporated under vacuo and solid product was 
recrystallized with ethanol/water. Oily product,  6a , was dis-
solved in diethylether. HCl gas was passed through the solution 
and solid hydrochloride salt of compound was obtained. Com-
pound needed no further purifi cation.
 1-[2-(Trifl uoromethoxy)phenylsulfonyl]-
4-(diphenylmethyl)piperazine hydrochloride (6a)
 White, opaque, powdered crystals. Yield: 10 % (0.05 g); m.p.: 
205.8 °C. UV (MeOH, λ max , nm); 204 (log ε: 5.24), 226 (log ε: 
4.87). FT - IR (KBr, cm  − 1 ); 3 445 (N-H), 3 007 (C-H, aromatic), 
2 909 (C-H, aliphatic), 1 590 (C = C, aromatic), 1 353 (S = O, asym.), 
1 282 (C-O), 1 248 (C-F), 1 209 (C-N), 1 167 (S = O, sym.).  1 H-NMR 
(DMSO, ppm); 3.21–3.38 (m, 4H, piperazine H 3 , H 5 ); 3.74 (m, 4H, 
piperazine H 2 , H 6 ); 5.57 (d, 1H, (Ar) 2 CH-,  J = 8.4 Hz ); 7.31–7.89 
(m, 14H, aromatic H’s); 12.5 (bs, 1H, N-H salt). MS (m/z); 477.8 
(100 %, M  +  – Cl); 167.6 ((C 6 H 5 ) 2 CH⎤  +  ). Anal. calcd. for C 24 H 24 ClF-
 3 N 2 O 3 S (512.97): C, 56.19; H, 4.72; N, 5.46; S, 6.25. C, 55.85; H, 
4.82; N, 5.80; S, 6.21.
 1-[2-(Trifl uoromethyl)phenylsulfonyl]-4-[(bis
(4-fl uorophenyl)methyl]piperazine (6b)
 Colourless, shiny, prism-shaped crystals. Yield: 22 % (0.112 g); 
m.p.: 135.6 °C. UV (MeOH, λ max , nm): 203 (log ε: 5.16), 225 (log 
ε: 4.67). FT - IR (KBr, cm  − 1 ); 3 074 (C-H, aromatic), 2 917 (C-H, 
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aliphatic), 1 604 (C = C, aromatic), 1 370 (S = O, asym.), 1 284 
(C-N), 1 218 (C-F), 1 144 (S = O, sym.).  1 H-NMR (DMSO, ppm); 
2.35 (bs, 4H, piperazine H 3 , H 5 ); 3.18 (bs, 4H, piperazine H 2 , H 6 ); 
4.45 (s, 1H, (Ar) 2 CH-); 7.11 (t, 4H, diphenyl H 3,5,3′,5′ ,  J = 9.2 Hz ); 
7.39–7.43 (dd, 4H, diphenyl H 2,6,2′,6′ ,  J 1 = 5.6 Hz, J 2 = 3.2 Hz ); 7.91–
8.06 (m, 4H, 2-trifl uoro-methylphenyl). Anal. calcd. for C 24 H 21 F-
 5 N 2 O 2 S (496.49): C, 58.06; H, 4.26; N, 5.64; S, 6.46. Found: C, 
58.19; H, 4.22; N, 5.79; S, 6.58.
 1-[(2,4,5-Trichlorophenyl)sulfonyl]-4-[bis(4-
fl uorophenyl)methyl]piperazine (6c)
 White, shiny, needle-shaped crystals. Yield: 11 % (0.060 g), m.p.: 
Above 300 °C. UV (MeOH, λ max , nm); 204 (log ε: 5.09), 225 (log ε: 
4.79). FT - IR (KBr, cm  − 1 ); 3 089 (C-H, aromatic), 2 969 (C-H, 
aliphatic), 1 602 (C = C, aromatic), 1 373 (S = O, asym.), 1 282 
(C-N), 1 219 (C-F), 1 153 (S = O, sym.), 1 097 (C-Cl).  1 H-NMR 
(DMSO, ppm); 2.32 (bs, 4H, piperazine H 3 , H 5 ); 3.24 (bs, 4H, pip-
erazine H 2 , H 6 ); 4.45 (s, 1H, (Ar) 2 CH-); 7.11 (t, 4H, diphenyl 
H 3,5,3′,5′ ,  J = 8.4 Hz ); 7.39–7.43 (dd, 4H, diphenyl H 2,6,2′,6′ ,  J 1 = 5.6 Hz, 
J 2 = 3.2 Hz ); 8.05 (s, 1H, 2,4,5-trichlorophenyl, H 6 ); 8.17 (s, 1H, 
2,4,5-trichlorophenyl, H 3 ). Anal. calcd. for C 23 H 19 Cl 3 F 2 N 2 O 2 S 
(531.83): C, 51.94; H, 3.60; N, 5.27; S 6.03. Found: C, 51.73; H, 
3.82; N, 5.56; S, 6.10.
 1-[(3,4-Dichlorophenyl)sulfonyl]-4-[bis(4-fl uorophenyl)
methyl]piperazine (6d)
 White, opaque, powdered crystals. Yield: 42 % (0.210 g); m.p.: 
145.1 °C. UV (MeOH, λ max , nm); 203 (log ε: 5.35), 227 (log ε: 
4.46). FT - IR (KBr, cm  − 1 ); 3 088 (C-H, aromatic), 2 979 (C-H, 
aliphatic), 1 602 (C = C, aromatic), 1 355 (S = O, asym.), 1 286 
(C-N), 1 220 (C-F), 1 175 (S = O, sym.), 1 031 (C-Cl).  1 H-NMR 
(DMSO, ppm); 2.35 (bs, 4H, piperazine H 3 , H 5 ); 2.98 (bs, 4H, pip-
erazine H 2 , H 6 ); 4.42 (s, 1H, (Ar) 2 CH-); 7.09 (t, 4H, diphenyl 
H 3,5,3′,5′ ,  J = 8.8 Hz ); 7.37–7.40 (dd, 4H, diphenyl H 2,6,2′,6′ ,  J 1 = 5.6 Hz, 
J 2 = 3.2 Hz ); 7.69–7.97 (m, 3H, 3,4-dichlorophenyl). Anal. calcd. 
for C 23 H 20 Cl 2 F 2 N 2 O 2 S (497.38): C, 55.54; H, 4.05; N, 5.63; S, 6.45. 
Found: C, 55.70; H, 4.11; N, 5.92; S, 6.57.
 1-[(o-Toluyl)sulfonyl]-4-[bis(4-fl uorophenyl)methyl]
piperazine (6e)
 White, opaque, powdered crystals. Yield: 10 % (0.05 g); m.p.: 
117.7 °C. UV (MeOH, λ max , nm); 206 (log ε: 5.32), 225 (log ε: 
4.67). FT - IR (KBr, cm  − 1 ); 3 068 (C-H, aromatic), 2 968 (C-H, 
aliphatic), 1 601 (C = C, aromatic), 1 342 (S = O, asym.), 1 229 
(C-N), 1 221 (C-F), 1 156 (S = O, sym.).  1 H-NMR (DMSO, ppm); 
2.33 (bs, 4H, piperazine H 3 , H 5 ); 2.55 (s, 3H, -CH 3 ); 3.04 (bs, 4H, 
piperazine H 2 , H 6 ); 4.41 (s, 1H, (Ar) 2 CH-); 7.10 (t, 4H, diphenyl 
H 3,5,3′,5′ ,  J = 8.8 Hz ); 7.38–7.41 (dd, 4H, diphenyl H 2,6,2′,6′ ,  J 1 = 5.6 Hz, 
J 2 = 3.2 Hz ); 7.42–7.47 (dd, 2H, 2-methylphenyl H 3,5 ,  J 1 = 5.2 Hz, 
J 2 = 7.6 Hz ); 7.57–7.62 (dd, 1H, 2-methylphenyl H 4 ,  J 1 = 1.2 Hz, 
J 2 = 7.2 Hz ); 7.75–7.77 (dd, 1H, 2-methylphenyl H 6 ,  J 1 = 1.2 Hz, 
J 2 = 6.8 Hz ). Anal. calcd. for C 23 H 20 Cl 2 F 2 N 2 O 2 S (497.38); C, 65.14; 
H, 5.47; N, 6.33; S, 7.25. Found: C, 65.51; H, 5.30; N 6.56; S 7.37.
 1-[(4-Nitrophenyl)sulfonyl]-4-[bis(4-fl uorophenyl)
methyl]piperazine (6f, CAS No: 1286459-36-6)
 Yellowish orange, shiny, powdered crystals. Yield: 13 % (0.06 g); 
m.p.: 224.5 °C. UV (MeOH, λ max , nm): 203 (log ε: 5.23), 225 (log 
ε: 4.39). FT - IR (KBr, cm  − 1 ); 3 070 (C-H, aromatic), 2 996 (C-H, 
aliphatic), 1 604 (C = C, aromatic), 1 527 (N = O), 1 359 (S = O, 
asym.), 1 224 (C-N), 1 213 (C-F), 1 172 (S = O, sym.).  1 H-NMR 
(DMSO, ppm); 2.35 (bs, 4H, piperazine H 3 , H 5 ); 2.99 (bs, 4H, pip-
erazine H 2 , H 6 ); 4.42 (s, 1H, (Ar) 2 CH-); 7.09 (t, 4H, diphenyl 
H 3,5,3′,5′ ,  J = 8 Hz ); 7.35–7.38 (dd, 4H, diphenyl H 2,6,2′,6′ ,  J 1 = 5.2 Hz, 
J 2 = 3.2 Hz ); 7.99 (d, 2H, 4-nitrophenyl H 2,6 ,  J = 9.2 Hz ); 8.47 (d, 2H, 
4-nitrophenyl H 3,5 ,  J = 8.8 Hz ). Anal. calcd. for C 23 H 21 F 2 N 3 O 4 S 
(473.49): C, 58.34; H, 4.47; N, 8.87; S, 6.77. Found: C, 57.75; H, 
4.56; N, 8.91; S, 6.83.
 1-[(2,5-Dichlorophenyl)sulfonyl]-4-[bis(4-fl uorophenyl)
methyl]piperazine (6g)
 Colourless, shiny, prism-shaped crystals. Yield: 23 % (0.115 g); 
m.p.: 116.1 °C. UV (MeOH, λ max , nm): 205 (log ε: 5.19), 224 (log 
ε: 4.91). FT - IR (KBr, cm  − 1 ); 3 003 (C-H, aromatic), 2 966 (C-H, 
aliphatic), 1 603 (C = C, aromatic), 1 375 (S = O, asym.), 1 284 
(C-N), 1 218 (C-F), 1 178 (S = O, sym.), 1 009 (C-Cl).  1 H-NMR 
(DMSO, ppm); 2.33 (bs, 4H, piperazine H 3 , H 5 ); 3.23 (bs, 4H, pip-
erazine H 2 , H 6 ); 4.44 (s, 1H, (Ar) 2 CH-); 7.11 (t, 4H, diphenyl 
H 3,5,3′,5′ ,  J = 8.4 Hz ); 7.39–7.43 (dd, 4H, diphenyl H 2,6,2′,6′ ,  J 1 = 5.6 Hz, 
J 2 = 3.2 Hz ); 7.75–7.81 (m, 2H, 2,5-dichlorophenyl H 3 , H 4 ); 7.9 (d, 
1H, 2,5-dichlorophenyl H 6 ,  J = 2.4 Hz ).  13 C-NMR (DMSO, ppm); 
46.39 (C 14,16 ); 51.28 (C 15,17 ); 72.82 (C 7 ); 115.95–116.16 (C 3,10 ); 
130.02–130.10 (C 2,9 ); 130.48 (C 20 ); 131.61 (C 21 ); 132.99 (C 23 ); 
134.79 (C 22 ); 135.02 (C 19 ); 137.34 (C 18 ); 138.83–138.85 (C 1,8 ); 
160.57–162.99 (C 4,11 ). MS (m/z); 497.98 (25 %, M  +  ); 499.8 (12 %, 
M + 2); 203.5 (100 %, (4-F-C 6 H 5 ) 2 CH⎤  +  ). Anal. calcd. for 
C 23 H 20 Cl 2 F 2 N 2 O 2 S (497.38): C, 55.54; H, 4.05; N, 5.63; S, 6.45. 
Found: C, 55.55; H, 3.89; N, 5.89; S, 6.58.
 1-[(2,4,5-Trichlorophenyl)sulfonyl]-4-[(4-chlorophenyl)
(phenyl)methyl]piperazine (6 h)
 White, opaque, powdered crystals. Yield: 19 % (0.100 g); m.p.: 
151.1 °C. UV (MeOH, λ max , nm): 205 (log ε: 4.66), 234 (log ε: 
4.09). FT - IR (KBr, cm  − 1 ); 3 091 (C-H, aromatic), 2 967 (C-H, 
aliphatic), 1 568 (C = C, aromatic), 1 352 (S = O, asym.), 1 283 
(C-N), 1 164 (S = O, sym.), 1 066 (C-Cl).  1 H-NMR (DMSO, ppm); 
2.29 (bs, 4H, piperazine H 3 , H 5 ); 3.21 (bs, 4H, piperazine H 2 , H 6 ); 
4.37 (s, 1H, (Ar) 2 CH-); 7.16 (t, 2H, phenyl H 3,5 ,  J = 6.8 Hz ); 7.27 (t, 
1H, phenyl H 4 ,  J = 7.6 Hz ); 7.29–7.35 (dd, 4H, 4-chlorophenyl H’s, 
 J 1 = 8.4 Hz, J 2 = 4.4 Hz ); 7.37 (d, 2H, phenyl H 2,6 ,  J = 8.4 Hz ); 8.016 (s, 
1H, 2,4,5-trichlorophenyl H 6 ); 8.14 (s, 1H, 2,4,5- trichlorophenyl 
H 3 ). Anal. calcd. for C 23 H 20 Cl 4 N 2 O 2 S (530.29): C, 52.09; H, 3.80; 
N, 5.28; S, 6.05. Found: C, 52.22; H, 4.00; N, 5.52; S, 6.19.
 1-[(3,4-Dichlorophenyl)sulfonyl]-4-[(4-chlorophenyl)
(phenyl)methyl]piperazine (6i)
 White, opaque, powdered crystals. Yield: 25 % (0.123 g); m.p.: 
107.1 °C. UV (MeOH, λ max , nm); 204 (log ε: 4.35), 236 (log ε: 
4.11). FT - IR (KBr, cm  − 1 ); 3 063 (C-H, aromatic), 2 965 (C-H, 
aliphatic), 1 560 (C = C, aromatic), 1 356 (S = O, asym.), 1 281 
(C-N), 1 172 (S = O, sym.), 1 033 (C-Cl).  1 H-NMR (DMSO, ppm); 
2.36 (bs, 4H, piperazine H 3 , H 5 ); 2.98 (bs, 4H, piperazine H 2 , H 6 ); 
4.37 (s, 1H, (Ar) 2 CH-); 7.18 (t, 2H, phenyl H 3,5 ,  J = 6.8 Hz ); 7.27 
(t, 1H, phenyl H 4 ,  J = 7.2 Hz ); 7.31–7.36 (dd, 4H, 4-chlorophenyl 
H’s,  J 1 = 8.4 Hz, J 2 = 3.6 Hz ); 7.39 (d, 2H, phenyl H 2,6 ,  J = 8.4 Hz ); 
7.69–7.97 (m, 3H, 3,4-dichlorophenyl H’s). Anal. calcd. for 
C 23 H 21 Cl 3 N 2 O 2 S (495.85): C, 55.71; H, 4.27; N, 5.65; S, 6.47. 
Found: C, 55.82; H, 4.35; N, 5.91; S, 6.51.
 1-[(4-Nitrophenyl)sulfonyl]-4-[(4-chlorophenyl)(phenyl)
methyl]piperazine (6j)
 Yellowish orange, opaque, cottonlike crystals. Yield: 37 % 
(0.175 g); m.p.: 209.3 °C. UV (MeOH, λ max , nm); 202 (log ε: 4.53), 
231 (log ε: 4.18), 264 (log ε: 3.82). FT - IR (KBr, cm  − 1 ); 3 055 (C-H, 
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aromatic), 2 947 (C-H, aliphatic), 1 606 (C = C, aromatic), 1 534 
(N = O), 1 356 (S = O, asym.), 1 281 (C-N), 1 170 (S = O, sym.), 1 088 
(C-Cl).  1 H-NMR (DMSO, ppm); 2.36 (bs, 4H, piperazine H 3 , H 5 ); 
2.99 (bs, 4H, piperazine H 2 , H 6 ); 4.38 (s, 1H, (Ar) 2 CH-); 7.18 (t, 
2H, phenyl H 3,5 ,  J = 7.2 Hz ); 7.26 (t, 1H, phenyl H 4 ,  J = 8 Hz ); 7.30–
7.34 (dd, 4H, 4-chlorophenyl H’s,  J 1 = 6.4 Hz, J 2 = 2 Hz ); 7.37 (d, 2H, 
phenyl H 2,6 ,  J = 8.8 Hz ); 8.01 (d, 2H, 4-nitrophenyl H 2 , H 6 , 
 J = 8.8 Hz ); 8.46 (d, 2H, 4-nitrophenyl H 3 , H 5 ,  J = 8.8 Hz ).  13 C-NMR 
(DMSO, ppm); 46.67 (C 14,16 ); 50.81 (C 15,17 ); 73.69 (C 7 ); 125.38 
(C 20,22 ); 127.79 (C 11 ); 128.08 (C 10,12 ); 129.18 (C 19,23 ); 129.29 
(C 9,13 ); 129.81 (C 2,6 ); 129.89 (C 3,5 ); 132.11 (C 4 ); 140.99 (C 1 ); 
141.92 (C 8 ); 142.29 (C 18 ); 150.76 (C 21 ). MS (m/z); 472.8 (25 %, 
M  +  ); 474.8 (12 %, M + 2); 201.5 (100 % (4-Cl-C 6 H 5 )-(C 6 H 5 )CH⎤  +  ); 
203.6 (38 %). Anal. calcd. for C 23 H 22 ClN 3 O 4 S (471.96); C, 58.53; H, 
4.70; N, 8.90; S, 6.79. Found: C, 58.56; H, 4.83; N, 8.99; S, 6.84.
 Cytotoxicity studies
 The cytotoxic activities of the synthesized compounds were inves-
tigated on liver (HUH-7), breast (MCF-7) and colon (HCT-116) can-
cer cell lines, by means of sulphorhodamine B (SRB) assays in 
triplicate. Serial dilutions from 100 μM to 2.5 μM were used, 5-fl uor-
ouracil (5-FU) was the reference compound and camptothecin 
(CPT) was the positive control for the cytotoxic eff ect.
 Cell culture
 The human cancer cell lines were grown in Dulbecco’s Modifi ed 
Eagle’s Medium (DMEM) supplemented with 10 % fetal bovine 
serum (FBS) and 1 % penicillin. Each cell line was maintained in 
an incubator at 37 °C supplied with 5 % CO 2 and 95 % air.
 NCI-60 Sulphorhodamine B (SRB) assay
 Cancer cells (range of 2 000 cell/well to 5 000 cell/well) were inocu-
lated into 96-well plates in 200 μl of media and incubated in 37 °C 
incubators containing 5 % CO 2 and 95 % air. After a 24 h incubation 
period, one plate for each cell line was fi xed with 100 μl 10 % ice-cold 
trichloroacetic acid (TCA). This plate represents the behavior of the 
cells just prior to drug treatment and is accepted as the time-zero 
plate. The compounds to be tested were solubilized in DMSO to a 
fi nal concentration of 40 mM and stored at  + 4 °C. While treating the 
cells with the stock compound solutions, the corresponding volume 
of the compound was applied to the cell to achieve the desired drug 
concentration and diluted through serial dilution. After drug treat-
ment, the cells were incubated in 37 °C incubators containing 5 % 
CO 2 and 95 % air for 72 h. Following the termination of the incuba-
tion period after drug treatment, the cells were fi xed with 100 μl 
10 % ice-cold TCA and incubated in the dark at  + 4 °C for 1 h. Then the 
TCA was washed away with ddH 2 O 5 times and the plates were left 
to air dry. For the fi nal step, the plates were stained with 100 μl of 
0.4 % sulphorhodamine B (SRB) solution in 1 % acetic acid solution. 
Following staining, the plates were incubated in dark for 10 min at 
room temperature. The unbound dye was washed away using 1 % 
acetic acid and the plates were left to air dry. To measure the absorb-
ance results, the bound stain was then solubilized using 200 μl of 
10 mM Tris-Base. The OD values were obtained at 515 nm.
 Results and Discussion
 ▼
 Chemistry
 The synthesis of the benzhydrylpiperazine derivatives  5a–6j is 
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 Fig. 1  Synthesis of compounds  5a–i and  6a–j 
 a TEA, DCM, benzoyl chlorides,  b TEA, DCM, 
sulfonyl chlorides. 
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 Reduction with sodium borohydride of benzophenone, 4-chlo-
robenzophenone and 4,4′-difl uorobenzophenone aff orded ben-
zhydrole derivatives which were chlorinated with HCl and 
anhydrous calcium chloride. Resulting benzhydryl chloride 
derivatives were used for  N -alkylation of piperazine to give 
1-benzhydrylpiperazine, 4-chlorobenzhydrylpiperazine and 
4,4′-difl uorobenzhydrylpiperazine. The fi nal step was nucle-
ophilic substitution with benzoyl chlorides or sulfonyl chlorides 
in order to obtain benzhydrylpiperazine derivatives  5a–6j. 
 Synthesized compounds were identifi ed with IR, UV and  1 H-
NMR spectra. In addition, some compounds were selected for 
LC-MS and  13 C-NMR spectral evaluation. In UV spectra of test 
compounds there are 2 signifi cant bands approximately at 205 
and 224 nm which represent π→π* and n→π* transitions of both 
series. In IR spectrum of  5a–i the stretching bands are observed 
nearly at 3 082 cm  − 1 (C-H; aromatic), 2 966 cm  − 1 (C-H; aliphatic), 
1 621 cm  − 1 (C = O), 1 583 cm  − 1 (C = C; aromatic) and 1 230 cm  − 1 
(C-N). In IR spectrum of  6a–j the stretching bands are observed 
nearly at 3 055 cm  − 1 (C-H; aromatic), 2 947 cm  − 1 (C-H; aliphatic), 
1 606 cm  − 1 (C = C; aromatic), 1 356 (S = O; asym.), 1 281 cm  − 1 
(C-N) and 1 170 cm  − 1 (S = O; sym.). In H 1 -NMR spectra of  5a–i 
protons of piperazine ring are seen in the range of 2.3 ppm and 
3.5 ppm as broad singlets. Diphenylmethyl C-H is observed as a 
singlet nearly at 4 ppm. Protons of aromatic rings give multiplet 
peaks at 6.91–7.46 ppm. In H 1 -NMR spectra of  6a–j protons of 
piperazine moiety are observed in the range of 2.3 ppm and 
3 ppm as broad singlets. Diphenylmethyl C-H is recognized as a 
singlet nearly at 4 ppm. Protons of chlorobenzhydryl group are 
seen as multiplets at 7.15–7.38 ppm. The  13 C-NMR spectrum of 
the compound  6j shows characteristic peaks of the sulfonamide 
derivatives at 46.67 and 50.81 ppm for piperazine ring and 
73.69 ppm for diphenylmethyl carbon. The  13 C-NMR spectrum 
of the compound  5a shows characteristic peaks of the benza-
mide derivatives at 43.09 and 51.49–51.74 ppm for piperazine 
ring, 75.2 ppm for diphenylmethyl carbon together with 
167.86 ppm for carbonyl carbon.
 The structures of the prepared benzhydrylpiperazine deriva-
tives are illustrated in   ●  ▶   Table 1 .
 Biological activity
 The cytotoxic activity of the synthesized compounds  5a–i and 
 6a–j was investigated on liver (HUH-7), breast (MCF-7) and 
colon (HCT-116) cancer cell lines, by means of sulphorhodamine 
B (SRB) assays in triplicate. As shown in   ●  ▶   Table 2 , all tested 
compounds were screened with mean 50 % growth inhibition 
concentration (GI 50 ) in micromolar concentration range.
 Generally, cytotoxic activities of sulfonamides increase when 
the core structure bears 4-chloro substitution on benzhydryl 
moiety. To exemplify this situation  6c and  6h or  6f and  6j can be 
compared with each other.  6c (R 1 , R 2 = F, R 3 = 2,4,5-trichloro, 
X = SO 2 ) has no inhibition against any of the cancer cell lines. 
Whereas,  6h (R 1 = Cl, R 2 = H, R 3 = 2,4,5-trichloro, X = SO 2 ) is slightly 
cytotoxic against all the cancer cell lines. Similarly,  6f (R 1 , R 2 = F, 
R 3 = 4-nitro, X = SO 2 ) has no cytotoxicity against any of the cancer 
cell lines. Whereas,  6j (R 1 = Cl, R 2 = H, R 3 = 4-nitro, X = SO 2 ) has 
variable cytotoxicity against all the cancer cell lines.






 Sample  X  R1  R2  R3  M. P. ( °C)  Yield ( %) 
 5a  C = O  - H  - H  5-Fluoro-2-methyl  > 300 (dec.)  95 
 5b  C = O  - F  - F  2-Bromo  189.7  35 
 5c  C = O  - F  - F  3-Bromo  151.4  27 
 5d  C = O  - F  - F  4-Bromo  > 300 (dec.)  19 
 5e  C = O  - F  - F  3-Chloro  177.5  47 
 5f  C = O  - Cl  - H  2-Methoxy  120  33 
 5g  C = O  - Cl  - H  3-Nitro  196.1  24 
 5h  C = O  - Cl  - H  3,4-Dimethoxy  148.6  11 
 5i  C = O  - Cl  - H  4-Ethyl  206.4  22 
 6a  SO 2   - H  - H  2-Trifl uoromethoxy  205.8  10 
 6b  SO 2   - F  - F  2-Trifl uoromethyl  135.6  22 
 6c  SO 2   - F  - F  2,4,5-Trichloro  > 300 (dec.)  11 
 6d  SO 2   - F  - F  3,4-Dichloro  145.1  42 
 6e  SO 2   - F  - F  2-Methyl  117.7  10 
 6f*  SO 2   - F  - F  4-Nitro  224.5  13 
 6g  SO 2   - F  - F  2,5-Dichloro  116.1  23 
 6h  SO 2   - Cl  - H  2,4,5-Trichloro  151.1  19 
 6i  SO 2   - Cl  - H  3,4-Dichloro  107.1  25 
 6j  SO 2   - Cl  - H  4-Nitro  209.3  37 
 L (*) 6f, CAS No: 1286459-36-6 
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 Benzoylpiperazines are moderately active on HUH-7 cell line 
and  5f (GI 50 = 8.49 μM) is the most active compound of the series.
 Sulfonylpiperazines show low or no inhibition on HUH-7 cell 
line in general, however  6i (GI 50 = 10.88 μM) has the highest 
activity among the sulfonylpiperazines.
 The most active compounds against MCF-7 cell line are  5d 
(GI 50 = 2.21 μM) and  6a (GI 50 = 4.50 μM). These highly cytotoxic 
compounds ( 5d and  6a ) were further evaluated for cytotoxicity 
against a normal-like breast epithelial cell line, MCF-12A, and 
found to be selective (see   ●  ▶   Table 3 ).
 Against MCF-7 cell line some of the sulfonamides ( 6b ,  6c ,  6f ,  6g , 
 6i ) show no inhibition. Interestingly, electron withdrawing halo-
gen substitution on phenyl ring of benzamide derivatives has 
elevated activity values as can be seen for compounds  5b 
(GI 50 = 6.05 μM),  5c (GI 50 = 5.95 μM),  5d (GI 50 = 2.21 μM) and  5e 
(GI 50 = 5.87 μM).
 Benzamide derivatives generally show good activity values con-
sidering HCT-116 cell line.  5c (GI 50 = 9.10 μM),  5e (GI 50 = 8.95 μM) 
and  5h (GI 50 = 9.45 μM) are the most active molecules among 
benzoylpiperazines. However, sulfonamides present low or no 
inhibition on HCT-116 cell line.
 Conclusion
 ▼
 In this study, 19 benzhydrylpiperazine derivatives with benza-
mide and sulfonamide moieties were prepared. In vitro cyto-
toxic activities were screened against hepatocellular (HUH-7), 
breast (MCF-7) and colorectal (HCT-116) cancer cell lines by sul-
phorhodamine B assay. Many compounds were found to have 
good inhibition values. In general, benzamide derivatives 
present better activities than sulfonamide derivatives. Addition-
ally, electron withdrawing substituents on phenyl ring of benza-
mide derivatives increased activity against MCF-7 cancer cell 
line. Future synthesis of similar derivatives will take place to cre-
ate a larger set of compounds in order to produce a rational 
quantitative structure-activity relationship (QSAR) mapping. 
Since 4-chloro-benzhydrylpiperazine derivatives are chiral com-
pounds, further exploration of chiral separation methods will be 
performed. The primary ambition regarding future research is to 
evaluate the mechanism of cytotoxicity.
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